Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial.
暂无分享,去创建一个
P. Ponikowski | J. McMurray | J. Lewsey | H. Krum | G. Bolli | W. Kothny | V. Lukashevich | P. Kozlovski
[1] G. Filippatos,et al. Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry , 2017, Diabetes Care.
[2] Matthew J. Crowley,et al. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease , 2017, Annals of Internal Medicine.
[3] D. Fitchett,et al. Heart failure outcomes in clinical trials of glucose‐lowering agents in patients with diabetes , 2017, European journal of heart failure.
[4] L. Tarnow,et al. Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double‐blind, randomised, placebo‐controlled trial , 2017, European journal of heart failure.
[5] Lawrence A Leiter,et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.
[6] K. Anstrom,et al. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. , 2016, JAMA.
[7] M. Pencina,et al. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. , 2016, JAMA cardiology.
[8] F. Porzsolt,et al. Using machine learning to predict laboratory test results , 2016, Annals of clinical biochemistry.
[9] S. Solomon,et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.
[10] Deepak L. Bhatt,et al. Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". , 2015, Circulation.
[11] M. Pencina,et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. , 2015, The New England journal of medicine.
[12] N. Chattipakorn,et al. Dipeptidyl peptidase‐4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction , 2015, Experimental physiology.
[13] W. Cushman,et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial , 2015, The Lancet.
[14] Deepak L. Bhatt,et al. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. , 2015, Circulation.
[15] Deepak L. Bhatt,et al. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial , 2014, Circulation.
[16] M. Pfeffer,et al. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. , 2014, The lancet. Diabetes & endocrinology.
[17] Craig Wilson,et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.
[18] Deepak L. Bhatt,et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.
[19] K. Connelly,et al. DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes. , 2013, Cardiovascular therapeutics.
[20] Yan-Ling He. Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin , 2012, Clinical Pharmacokinetics.
[21] P. Liu,et al. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta‐analysis of randomized clinical trials , 2012, Journal of clinical pharmacy and therapeutics.
[22] R. D. de Boer,et al. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure , 2011, Cardiovascular diabetology.
[23] Adrian V. Hernández,et al. Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus , 2011, American journal of cardiovascular drugs : drugs, devices, and other interventions.
[24] Markolf Hanefeld,et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial , 2010, European heart journal.
[25] Alfonso T. Perez,et al. Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. , 2009, Congestive heart failure.
[26] Karl Swedberg,et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. , 2008, European heart journal.
[27] R. McKelvie,et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. , 2008, European heart journal.
[28] J. McMurray,et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. , 2007, Journal of the American College of Cardiology.
[29] J. Cohn,et al. Ventricular remodeling in heart failure: a credible surrogate endpoint. , 2003, Journal of cardiac failure.
[30] S. Yusuf,et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. , 2000, European heart journal.
[31] J. Cohn,et al. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. , 2000, Journal of the American College of Cardiology.
[32] B. Brundage,et al. Left Ventricular Volume from Paired Biplane Two‐dimensional Echocardiography , 1979, Circulation.